Esketamine, Off-Label Ketamine, and the Regulatory Gap: A Conversation With Lisa Harding, MD
Psychiatrist Lisa Harding discusses the clinical use of intranasal esketamine and the regulatory challenges surrounding off-label ketamine treatments. She highlights that the MDSI indication for suicidality remains underutilized by clinicians.
Why it matters
It sheds light on the evolving landscape of interventional psychiatry and the need for better clinical comfort and standardized protocols for rapid-acting antidepressants.
TALKING WITH TITANS
At the 2026 Jersey City Psychiatry Conference, Psychiatric Times' Editor in Chief, John J. Miller, MD, sat down with leaders in the field to discuss the topics they find most important. On day 1 of the conference, he sat down with titan Lisa Harding, MD, a psychiatrist at Yale University in New Haven, Connecticut, who also works in private practice. They discussed how intranasal esketamine (Spravato) has been used clinically, how little its suicidality indication is used, and why off-label racemic ketamine faces so few rules.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in